Ascentage Pharma is a global biopharmaceutical company engaged in developing novel therapies for leukemias, solid tumors and sarcomas. The company has multiple on-going clinical trials in Phase I and II that involve the use of novel drug candidates and investigational agents such as third-generation tyrosine kinase inhibitors olverembatinib (HQP1351); Bcl-2 inhibitor lisaftoclax (APG-2575); MDM-p53 inhibitor alrizomadlin (APG-115); ALK inhibitor APG-2449; dual Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252) and epigenome-modifying agents (i.e., EED inhibitors) to address unmet medical needs.